Physician profile

Anthony E Loehr

Otolaryngology · Tulsa, OK

NPI 1528065331

$747.92

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$175.14

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Stryker Corporation $268.45 2019-2020
Acclarent, INC $124.51 2023 Trudi Nav Cable
Regeneron Healthcare Solutions, INC. $117.54 2019-2022
Alk-Abello, INC $80.34 2019-2023 Ragwitek, Grastek, Odactra
Optinose US, INC. $77.52 2019-2023
Novartis Pharmaceuticals Corporation $27.20 2019
Livanova USA, INC. $19.34 2022
Glaxosmithkline, LLC. $17.22 2023 Nucala
Sanofi-Aventis U.S. LLC $15.80 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anthony E Loehr

$747.92

in general payments reported 2019-2025

Years
2019-2023
Top company
Stryker Corporation

https://glasscript.com/doctor/341000/anthony-e-loehr

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.